放射線科YEN, RUOH-FANGRUOH-FANGYENJENG, YUNG-MINGYUNG-MINGJENGTZEN, KAI-YUANKAI-YUANTZENHSU, CHIUNCHIUNHSUHONG, RUEY-LONGRUEY-LONGHONG2008-12-242018-07-122008-12-242018-07-122005http://ntur.lib.ntu.edu.tw//handle/246246/93712Background. There is a lack of effective treatment for metastatic adenoid cystic carcinoma (ACC), a usually indolent tumor. We studied the efficacy of imatinib mesylate , a potent inhibitor of KIT tyrosine kinase, in patients with KIT-positive metastatic ACC. Methods. Five patients with lung metastasis were treated in a pilot study with imatinib 400 mg by mouth twice a day. Mutations of c-kit and platelet-derived growth factor receptor (PDGFR)-alpha in tumors from these patients were analyzed. Results. Disease progression was noted in three of five patients during the short treatment periods, ranging from 2 to 3 weeks. Three patients died of disease within 6 months. No detectable mutations were found in c- kit and PDGFR-alpha.en-USadenoid cystic carcinomaimatinib mesylateKITPDGFR